CA-DEXCOM
2.2.2021 16:02:12 CET | Business Wire | Press release
DexCom, Inc . (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its first-ever Super Bowl commercial , starring multi-platinum recording artist, actor and philanthropist Nick Jonas, who was diagnosed with Type 1 diabetes at the age of 13. The ad, which will run during Super Bowl LV on Feb. 7, 2021, calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005348/en/
“Too many people with diabetes suffer through painful, antiquated fingerpricks because they don’t know a better way exists,” said Jonas. “I truly believe people with diabetes deserve the absolute best care, and that’s really the spirit of my first Super Bowl commercial. It means so much to me to bring this message of awareness and the need for improved CGM access to as many people with diabetes as possible.”
Tens of millions of people with diabetes around the world are still pricking their fingers, signaling a lack of awareness and the need to improve access for game changing CGM technology that has revolutionized diabetes management.
The Dexcom G6 CGM system uses a small wearable sensor and transmitter to measure and send real-time glucose values wirelessly to a compatible smart device or receiver,* eliminating the need for painful fingerpricks. † Dexcom CGM also displays trend arrows to show the speed and direction glucose levels are heading, making in-the-moment treatment decisions easier and helping people with diabetes avoid potentially dangerous high or low glucose events.‡
The ad, which will air at the end of the first quarter, shows how much various technologies have advanced over the last 40 years—contrasted by the realization that people with diabetes are still pricking their fingers to measure their glucose, a method invented in the 1970s.
“We are very excited to partner with Nick to shed light on technology that we know can significantly improve the lives of people with diabetes,” said Chad Patterson, senior vice president of global marketing for Dexcom. “People with diabetes deserve the best care, so along with leading diabetes advocacy groups, healthcare professionals and payers we are trying to increase awareness and improve access for CGM.”
As COVID-19 persists, Super Bowl parties are expected to look very different this year. For people with diabetes, a group at higher risk of COVID-19-related complications, social distancing and avoiding large gatherings is especially important. To help people feel less isolated on Super Bowl Sunday, Dexcom is giving fans the opportunity to “watch the game” with Nick Jonas through an interactive augmented reality experience.
Visit DexcomGameDay.com to see the commercial and find out how to watch the Super Bowl with Nick Jonas.
While the Super Bowl offers an enormous stage to launch this important conversation, Dexcom and Nick Jonas will be teaming up with leading diabetes nonprofits in the coming weeks to continue the discussion about better awareness, education and access for diabetes management technology. Organizations involved in this effort will include Beyond Type 1, the nonprofit co-founded by Nick, Children with Diabetes, College Diabetes Network, JDRF International and Taking Control of Your Diabetes.
To learn more about Dexcom CGM, visit Dexcom.com
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. For more information, visit www.dexcom.com .
* For a list of compatible devices, visit www.dexcom.com/compatibility .
† If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ The urgent low soon can warn you in advance of severe hypoglycemia—allowing you time to take appropriate action before it happens.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005348/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 08:00:00 CEST | Press release
Approval expands XEOMIN use to include the symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2 to 17 years. Approval includes both children and adolescents who are able to walk and those who are non-ambulant, broadening the population eligible for XEOMIN treatment Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in childr
Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 08:00:00 CEST | Press release
Founding members endorse a Declaration of Intent centred on practical collaboration, meaningful patient participation and evidence-based improvement. The Network will address shared challenges including blood supply, unequal access to specialist care and innovation, real-world evidence and European policy change. Avanzanite Bioscience becomes Founding Sponsor to support an independent platform designed to connect expertise, highlight unmet needs and help turn scientific and patient knowledge into practical collaboration. The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives th
IKI Advances Promotional Forecast Accuracy by More Than 10 Points With SymphonyAI17.9.2026 07:03:00 CEST | Press release
Lithuania's second-largest grocer brings AI-driven promotional planning to its network of 250 stores, with early results already showing double-digit gains in forecast accuracy SymphonyAI, a global leader in Vertical AI, today announced that IKI, one of Lithuania's largest grocery retailers, is implementing SymphonyAI's Promotional Evaluation and Promotional Planning solutions across its network of 250 stores, as part of its strategy to strengthen data-driven promotional planning. IKI continuously evaluates opportunities to strengthen its category management and promotional planning capabilities. As promotional programs become increasingly sophisticated, the retailer has invested in advanced analytics and AI-driven forecasting to support data-driven decision making across its business. In its initial work with SymphonyAI across select categories, IKI has seen promotional forecast accuracy improve by more than 10 percentage points, along with a reduction in stock-outs during promotional
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA development while optimizing design performance and capability. "Accelerating time-to-market demands and rising design complexity are putting mounting pressure on FPGA developers to do more with every design cycle," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Lattice Prompt gives developers AI-assisted access to the full design flow, grounded in Lattice's validated knowledge, so they can focus on what matters most: building differentiated systems." Lattice Prompt:
Lattice Expands Secure Control FPGA Leadership with New Lattice Mach-N2 Family17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced Lattice Mach™-N2 FPGA family, extending its long-running secure control FPGA leadership with new devices purpose-built for system control and security in modern infrastructure. Built on the Lattice Nexus™ 2 small FPGA platform, Mach-N2 combines integrated flash, a hardware Root of Trust, and CNSA 2.0-compliant post-quantum cryptography (PQC) with crypto agility for trusted, always-on system control and security across next-generation systems. "The demands on system control and security are accelerating as post-quantum mandates take hold, and customers building long-lifecycle infrastructure seek solutions that will help them design with today and tomorrow’s security needs in mind," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Mach-N2 represents a significant step forward in logic density and bandwidth while adding the most complete post-qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom